On the day that almost 100 products switched from being regulated as drugs to biologics in the US – opening the door for the first time to applications for biosimilar and interchangeable versions – Sanofi’s Lantus (insulin glargine) stands alone as the only insulin product still listed in the “Orange Book.”
23 March was transition day for insulins, human growth hormone and other protein products originally approved as new drug applications....
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?